PD-034 Heterogeneity in the first-line treatment of patients with advanced or metastatic gastric cancer in the US

Lignende værker

• Molecular‐targeted first‐line therapy for advanced gastric cancer
  af: Song, Huan, et al.
  Udgivet: (2016)
• The relationship between Eastern Cooperative Oncology Group performance status and healthcare resource utilization among patients with advanced or metastatic colorectal, lung or gastric cancer
  af: Hess, Lisa M., et al.
  Udgivet: (2020)
• P-281 JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1 antibody) maintenance therapy vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer
  af: Julien, Taieb, et al.
  Udgivet: (2016)
• Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma
  af: Bullock, Andrea, et al.
  Udgivet: (2017)
• Establishment and validation of prognostic nomograms in first-line metastatic gastric cancer patients
  af: Narita, Yukiya, et al.
  Udgivet: (2018)